2,236 press releases in English indexed under biotech & pharma.
Grant supports Waypoint's Therapeutic Resources team and its free Youth Mental Health First Aid and Community Resiliency Model trainings Grant supports Waypoint's Therapeutic Resources team and its free Youth Mental Health First Aid and Community Resiliency Model trainings
SAN DIEGO, Oct. 19, 2026 -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today announced that GSK has received U.S. Food and Drug Administration (FDA) approval for Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/ mismatch repair deficient (dMMR) locally advanced rectal cancer.
Ardelyx, Inc. faces allegations that it misled investors regarding the true state of its commercial performance and growth prospects of its two core drugs.
DIAPIN Therapeutics and Adelle Diagnostics win Gold at Rockefeller Center NEW YORK, Oct. 19, 2026 -- Jessica Reed, CEO, DIAPIN Therapeutics, and Maria Grazia Ruocco, CEO/Co-Founder, Adelle Diagnostics, won PRODUCT and CONCEPT Gold at the fifth annual Medical Innovation...
The migraine market is expected to grow steadily over the forecast period (2026–2036) driven by the rising global prevalence of migraine, improving diagnosis rates, and increasing awareness of chronic and high-frequency migraine. In addition, the introduction of novel, differentiated therapies such as Elismetrep (Kallyope), Dysport (abobotulinumtoxinA; Ipsen), Xeomin (incobotulinumtoxinA; Merz Therapeutics GmbH), Bocunebart (AG09222; Lundbeck), EVO756 (Evommune), and others that move beyond traditional acute treatments is expected to further expand the market. The migraine market is expected to grow steadily over the forecast period (2026–2036) driven by the rising global prevalence of migraine, improving diagnosis rates, and increasing awareness of chronic and high-frequency migraine. In addition, the introduction of novel, differentiated therapies such as Elismetrep (Kallyope), Dysport (abobotulinumtoxinA; Ipsen), Xeomin (incobotulinumtoxinA; Merz Therapeutics GmbH), Bocunebart (AG09222; Lundbeck), EVO756 (Evommune), and others that move beyond traditional acute treatments is expected to further expand the market.
Positive pre-Investigational New Drug (pre-IND) interaction with the Food Drug Administration (FDA) on Chemistry, Manufacturing and Controls (CMC) and nonclinical topics supports MaaT034's continued advancement FDA alignment on the IND-enabling strategy indicates that no additional non-clinical studies are anticipated to
Optimize ROI by targeting antibody-drug conjugates, subcutaneous delivery and Asia-Pacific expansion, backed by segment insights and competitive benchmarking. Optimize ROI by targeting antibody-drug conjugates, subcutaneous delivery and Asia-Pacific expansion, backed by segment insights and competitive benchmarking.
VILLEJUIF, France, October 19, 2026--Orano Med, a subsidiary of the Orano group specializing in nuclear medicine, today announced the appointment of Matthew Fyfe as Chief Scientific Officer. Dr. Fyfe is a seasoned drug hunter with more than 25 years' experience in successful drug discovery and developm
State laws that make pharmacist immunization depend on federal ACIP action can reduce or restrict adults' access to vaccines at their neighborhood pharmacies. The report lays out a three-tier legal framework states can adopt now. UPPER NYACK, N.Y., October 19, 2026--As federal vaccine policy remains in
Panel on chronic conditions and off-target effects of vaccines, and a presentation on Pinion's EBV immunotherapeutic program ROCKVILLE, Md., October 19, 2026--Pinion Immunotherapeutics, a clinical-stage biotechnology company developing AI-designed mRNA immunotherapeutics for latent viral infections and
MENLO PARK, Calif., October 19, 2026--Hippocratic AI today announced seven senior executive appointments spanning operations, legal, government solutions, pharma, global partnerships, marketing, and finance. The hires follow the company's August 13 launch of Agentic Orchestrators — teams of conversatio
FDA Clearance of Investigational New Drug Application for PVT201, in development for the treatment of autoimmune liver disease and prevention of organ transplant rejection, is the first candidate from the Parvus nanomedicine immune tolerance platform to clear an IND. [PR.com]